
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics Corp has demonstrated a consistent quarter-over-quarter growth in utilization of its systems, with an average increase of approximately 6.1% over the last six quarters. The company has strategically aimed to manage its operating expenses, intending to grow them at half the rate of top-line growth, which has been positively received by the market and suggests a clearer path to profitability. Looking ahead, implied handpiece utilization growth is projected to accelerate in FY26, hinting at potential revenue expansion as the company capitalizes on its innovative robotic systems in the urology sector.
Bears say
PROCEPT BioRobotics Corp has experienced a substantial decline in its stock value, with shares down approximately 54% year-to-date, despite the company’s ability to exceed its own financial guidance. The company's outlook is further complicated by potential downside risks, including a forecasted decline in capital equipment demand, reduced handpiece usage from existing customers, and intensified competitive pressures within the surgical robotics market. Additionally, impending changes to reimbursement policies for Aquablation therapy could adversely impact the company's revenue streams, further exacerbating concerns about its financial performance.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares